Podcast Episodes
Back to Search
Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals
FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen …
3 months, 3 weeks ago
Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss; CVC Bids $12.6B for Recordati
Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B…
3 months, 3 weeks ago
Mar 25, 2026 | Merck's $6.7B Terns Acquisition for CML Drug TERN-701
Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the firs…
3 months, 4 weeks ago
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medi…
3 months, 4 weeks ago
Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal
Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Ar…
4 months ago
Mar 22, 2026 | Abbott's $21B Exact Sciences Deal Closes; Wegovy HD Approved, Orforglipron Delayed
Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron…
4 months ago
Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma
Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins …
4 months ago
Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days
Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same da…
4 months ago
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead canc…
4 months ago
Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%
Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfiz…
4 months ago